Molecular mechanisms of Mycobacterium tuberculosis resistance to reserve-series drugs



Cite item

Full Text

Abstract

The review presents the data currently available in the literature on the mechanisms responsible for the development of resistance in Mycobacterium tuberculosis to reserve-series drugs, such as prothionamide, ethionamide, kanamycin, amikacin, capreomycin, cycloserine, rifabutin, PAS, and a group of fluoroquinolones.

About the authors

Anastasiya Valer'evna Nizova

Email: info@obolensk.org; anastasiya@mail.ru

Valentina Nikolaevna Stepanshina

Email: info@obolensk.org

Igor' Georgievich Shemyakin

Email: info@obolensk.org

A V Nizova

State Research Center of Applied Microbiology and Biotechnology

State Research Center of Applied Microbiology and Biotechnology

V N Stepanshina

State Research Center of Applied Microbiology and Biotechnology

State Research Center of Applied Microbiology and Biotechnology

I G Shemyakin

State Research Center of Applied Microbiology and Biotechnology

State Research Center of Applied Microbiology and Biotechnology

References

  1. Кузьмин А. В., Васильева И. А., Черноусова Л. Н. Эффективность химиотерапии деструктивного туберкулеза легких, основанной на результатах экспресс-детекции лекарственной чувствительности к изониазиду и рифампицину тест-системой ТБ-биочип // Пробл. туб. и бол. легких. - 2006. - № 8. - С. 17-23.
  2. Мишин В. Ю., Чуканов В. И., Васильева И. А. К проблеме оптимизации и доказательности современных режимов химиотерапии туберкулеза легких // Пробл. туб. и бол. легких. - 2004. - № 8. - С. 7-11.
  3. Носова Е. Ю., Галкина К. Ю., Маркова О. В. и др. Изучение лекарственной чувствительности Mycobacterium tuberculosis к фторхинолонам путем выявления мутаций в гене gyrA // Пробл. туб. и бол. легких. - 2007. - № 10. - С. 57-60.
  4. Приказ Министерства здравоохранения РФ № 109 от 21 марта 2003 г. О совершенствовании противотуберкулезных мероприятий в Российской Федерации. - М., 2003.
  5. Туберкулез. Патогенез, защита, контроль / Под ред. Барри Р. Блума; пер. с англ. - М., 2002.
  6. Alangaden G. J., Kreiswirth B. N., Aouad A. et al. // Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 1998. - Vol. 42, N 5. - P. 1295-1297.
  7. Aubry A., Veziris N., Cambau E. et al. Novel gyrase mutations in quinolone-resistant and hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes // Antimicrob. Agents Chemother. - 2006. - Vol. 50, N 1. - P. 104-112.
  8. Banerjee A., Dubnau E., Quemard A. et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis // Science. - 1994. - Vol. 263, N 5144. - P. 227- 230.
  9. Baulard A. R., Betts J. C., Endohang-Ndong J. et al. Activation of the pro-drug ethionamide is regulated in mycobacteria // J. Biol. Chem. - 2000. - Vol. 275, N 36. - P. 28326-28331.
  10. Ca'ceres N. E., Harris N. B., Wellehan J. F. et al. Overexpression of the D-Alanine racemase gene confers resistance to D-Cycloserine in Mycobacterium smegmatis // J. Bacteriol. - 1997. - Vol. 179, N 16. - P. 5046-5055.
  11. Chan R. C. Y., Hui M., Chan E. W. C. et al. // Genetic and phenotypic characterization if drug-resistant Mycobacterium tuberculosis isolates in Hong Kong // J. Antimicrob. Chemother. - 2007. - Vol. 59, N 1. - P. 866-873.
  12. Chikamatsu K., Mizuno K., Yamada H., Mitarai S. Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains // Kekkaku. - 2009. - Vol. 84, N 9. - P. 631-633.
  13. David H. L. Resistance to D-Cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants // J. Bacteriol. - 1971. - Vol. 21, N 5. - P. 888-892.
  14. DeBarber A. E., Mdluli K., Bosman M. et al. Ethionamide activation and sensitivity in multidrug resistant Mycobacterium tuberculosis // Proc. Natl Acad. Sci. USA. - 2000. - Vol. 97, N 17. - P. 9677-9682.
  15. Devasia R. A., Blackman A., May C. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance // J. Antimicrob. Chemother. - 2009. - Vol. 63, N 6. - P. 1173-1178.
  16. Drlica K., Zhao X. DNA Gyrase, Topoisomerase IV, and the 4-Quinolones // Microbiol. Mol. Biol. Rev. - 1997. - Vol. 61, N 3. - P. 377-392.
  17. Engohang-Ndong J., Baillat D., Aumercier M. et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator // Mol. Microbiol. - 2004. - Vol. 51, N 1. - P. 175- 188.
  18. Felnagle E. A., Rondon M. R., Berti A. D. et al. Identification of the biosynthetic gene cluster and an additional gene for resistance to the antituberculosis drug capreomycin // J. Antimicrob. Chemother. - 2007. - Vol. 73, N 13. - P. 4162-4170.
  19. Feng Z., Barletta R. G. Roles of Mycobacterium smegmatis D-Alanine: D-Alanine Ligase and D-Alanine Racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-Cycloserine // Antimicrob. Agents Chemother. - 2003. - Vol. 47, N 1. - P. 283-291.
  20. Feuerriegel S., Cox H. S., Zarkua N. et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients, undergoing treatment // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 8. - P. 3353-3356.
  21. Giannoni F., Iona E., Sementilli F. et al. Evaluation of new line probe assay for rapid identification of gyr A mutations in Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 2005. - Vol. 49, N 7. - P. 2928-2933.
  22. Herr E. B. Jr., Redstone M. O. Chemical and physical characterization of capreomycin // Ann. N. Y. Acad. Sci. - 1966. - Vol. 135. - P. 940-946.
  23. Hillemann D.,* Rusch-Gerdes S., Richter E. Feasibility of the Geno Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strain and clinical specimens // J. Clin. Microbiol. - 2009. - Vol. 47, N 6. - P. 1767-1772.
  24. Ji B., Truffot-Pernot C., Lacroix C. et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tubercolosis in mice // Am. Rev. Respir. Dis. - 1993. - Vol. 148. - P. 1541-1546.
  25. Johansen S. K., Maus C. E., Plikaytis B. B., Douthwaite S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 20-O-methylations in 16S and 23S rRNAs // Mol. Cell. - 2006. - Vol. 23. - P. 173-182.
  26. Johnson R., Streicher E. M., Louw G. E. et al. Drug resistance in Mycobacterium tuberculosis // Curr. Issues Mol. Biol. - 2005. - Vol. 8. - P. 97-112.
  27. Jugheli L., Bzekalava N., de Rijk P. et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gent // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 12. - P. 5064- 5068.
  28. Kocagöz T., Hackbarth C. J., Unsal I. et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra // J. Antimicrob. Chemother. - 1996. - Vol. 40, N 87. - P. 1768-1774.
  29. Koseki Y., Okamoto S. Studies on sross-resistance between capreomycin and certain other antimycobacterial agants // Jpn J. Med. Sci. Biol. - 1963. - Vol. 16. - P. 31-38.
  30. Larsen M. H., Vilchéze C., Kremer L. et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis // Mol. Microbiol. - 2002. - Vol. 46, N 2. - P. 453-466.
  31. Marrakchi H., Laneelle G., Quemard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II // Microbiology. - 2000. - Vol. 146. - P. 289-296.
  32. Mathys V., Wintjens R., Lefevre P. et al. Molecular genetics of paraaminosalicylie acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 5. - P. 2100-2109.
  33. Maus C. E., Plikaytis B. B., Shinnick T. M. Molecular analysis cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 8. - P. 3192-3197.
  34. Maus C. E., Plikaytis B. B., Shinnick T. M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 2. - P. 571-577.
  35. McClatchy J. K., Kanes W., Davidson P. T., Moulding T. S. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin // Tubercle. - 1977. - Vol. 58. - P. 29-34.
  36. Mdluli K., Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery // Infect. Disord. Drug Targets. - 2007. - Vol. 7, N 2. - P. 159-168.
  37. Mokrousov I., Otten T., Manicheva O. et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia // Antimicrob. Agents Chemother. - 2008. - Vol. 52, N 8. - P. 2937-2939.
  38. Morlock G. P., Metchock B., Sikes D. et al. EthA, inhA, and katG Loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates // Antimicrob. Agents Chemother. - 2003. - Vol. 47, N 12. - P. 3799-3805.
  39. Peteroy M., Severin A., Zhao F. et al. Characterization of a Mycobacterium smegmatis mutant that is simultaneously resistant to D-Cycloserine and Vancomycin // Antimicrob. Agents Chemother. - 2000. - Vol. 44, N 6. - P. 1701-1704.
  40. Petry Jr. W. Chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy // Goodman & Gilman The pharmacological Basis of Therapeutics / Brunton L. L. et al. - 2006. - P. 1203-1223.
  41. Pitaksajjakul P., Wongwit W., Punprasit W. et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand // Southeast Asian J. Trop. Med. Publ. Hlth. - 2005. - Vol. 36, N 4. - P. 228-237.
  42. Rengarajan J., Sassetti C. M., Naroditskaya V. et al. The folate pathway is a target for resistance to the drug para-aminosalicylie acid (PAS) in mycobacteria // Mol. Microbiol. - 2004. - Vol. 53, N 1. - P. 275-282.
  43. Shi R., Zhang J., Li C. et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing // J. Clin. Microbiol. - 2006. - Vol. 44, N 12. - P. 4566-4568.
  44. Sreevatsan S., Pan X., Stockbauer K. E. et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination // Proc. Natl Acal. Sci. USA. - 1997. - Vol. 94. - P. 9869- 9874.
  45. Sugawara I., Zhang J., Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin // Indian J. Exp. Biol. - 2009. - Vol. 47, N 6. - P. 520-522.
  46. Sun Z., Zhang J., Zhang X. et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates // Int. J. Antimicrob. Agents. - 2008. - Vol. 31. - P. 115-121.
  47. Sutton W. B., Gordee R. S., Wick W. E., Standfield L. V. In vitro and in vivo laboratory studies on the antituberculosis activity of capreomycin // Ann. N. Y. Acad. Sci. - 1966. - Vol. 135. - P. 947-959.
  48. Suzuki Y., Katsukawa C., Tamaru A. et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene // J. Clin. Microbiol. - 1998. - Vol. 36, N 5. - P. 1220-1225.
  49. Taniguchi H., Chang B., Abe C. et al. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system // J. Bacteriol. - 1997. - Vol. 179, N 15. - P. 4795-4801.
  50. Tsukamura M. Cross-resistance relationships between capreomycin, kanamycin and viomycin resistance in tubercle bacilli from patients // Am. Rev. Respir. Dis. - 1969. - Vol. 99. - P. 780-782.
  51. Tyagi J. S., Sharma D. Mycobacterium smegmatis and tuberculosis // Trends Microbiol. - 2002. - Vol. 10, N 2. - P. 68- 69.
  52. Uzun M., Erturan Z. O. An investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains // J. Tuberc. Lung Dis. - 2002. - Vol. 6, N 2. - P. 164-165.
  53. Vilchéze C., Weisbrod T. R., Chen B. et al. Altered NADH/ NAD+ ratio mediates coresistance to isoniazid and ethionamide in Mycobacteria // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 2. - P. 708-720.
  54. Vilchéze C., Av-Gay Y., Attarian R. et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis // Mol. Microbiol. - 2008. - Vol. 69, N 5. - P. 1316-1329.
  55. Wang J. C. DNA topoisomerases // Annu. Rev. Biochem. - 1985. - Vol. 54. - P. 665-597.
  56. Wang J.-Y., Lee L.-N., Lai H.-C. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure // J. Antimicrob. Chemother. - 2007. - Vol. 59. - P. 860-865.
  57. Wargel R. J., Shadur C. A., Neuhaus F. C. Mechanism of D-Cycloserine action: transport mutants for D-Alanine, D-Cycloserine, and Glycinel // J. Bacteriol. - 1971. - Vol. 105, N 3. - P. 1028-1035.
  58. Winder F. G., Collins P. B., Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG // J. Gen. Microbiol. - 1971. - Vol. 68. - P. 1037-1044.
  59. Xu P., Li X., Zhao M. et al. Prevalence of fluoroquiolone resistance among tuberculosis patients in Shanghai, China // J. Antimicrob. Chemother. - 2009. - Vol. 53, N 7. - P. 3170-3172.
  60. Yang B., Koga H., Ohno H. et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 1998. - Vol. 42, N 5. - P. 621-628.
  61. Zhang Y. The magic bullets and tuberculosis drug targets // Annu. Rev. Pharmacol. Toxicol. - 2005. - Vol. 45. - P. 529- 564.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Eco-vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014448 от 08.02.1996. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 .


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies